These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 17663692)

  • 1. Successful prolonged rituximab treatment for post-transplant lymphoproliferative disorder following living donor liver transplantation in a child.
    Hayashida M; Ogita K; Matsuura T; Takahashi Y; Nishimoto Y; Ohga S; Hara T; Soejima Y; Taketomi A; Maehara Y; Kohashi K; Tsuneyoshi M; Taguchi T
    Pediatr Transplant; 2007 Sep; 11(6):671-5. PubMed ID: 17663692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intestinal perforation associated with rituximab therapy for post-transplant lymphoproliferative disorder after liver transplantation.
    Cornejo A; Bohnenblust M; Harris C; Abrahamian GA
    Cancer Chemother Pharmacol; 2009 Sep; 64(4):857-60. PubMed ID: 19588139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-transplant lymphoproliferative disorders after lung transplantation: first-line treatment with rituximab may induce complete remission.
    Knoop C; Kentos A; Remmelink M; Garbar C; Goldman S; Feremans W; Estenne M
    Clin Transplant; 2006; 20(2):179-87. PubMed ID: 16640524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab.
    Trappe R; Riess H; Babel N; Hummel M; Lehmkuhl H; Jonas S; Anagnostopoulos I; Papp-Vary M; Reinke P; Hetzer R; Dörken B; Oertel S
    Transplantation; 2007 Apr; 83(7):912-8. PubMed ID: 17460562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complete immunosuppressive withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation.
    Hurwitz M; Desai DM; Cox KL; Berquist WE; Esquivel CO; Millan MT
    Pediatr Transplant; 2004 Jun; 8(3):267-72. PubMed ID: 15176965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid response to rituximab in a pediatric liver transplant recipient with post-transplant lymphoproliferative disease and maintenance with sirolimus monotherapy.
    Al-Akash SI; Al Makadma AS; Al Omari MG
    Pediatr Transplant; 2005 Apr; 9(2):249-53. PubMed ID: 15787802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple clinical presentations of lymphoproliferative disorders in pediatric liver transplant recipients: a single-center experience.
    Pinho-Apezzato ML; Tannuri U; Tannuri AC; Mello ES; Lima F; Gibelli NE; Santos MM; Ayoub AA; Maksoud-Filho JG; Velhote MC; Silva MM; Andrade WC; Miyatani HT
    Transplant Proc; 2010 Jun; 42(5):1763-8. PubMed ID: 20620519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnosis and treatment of post-transplantation lymphoproliferative disorder in pediatric heart transplant patients.
    Schubert S; Abdul-Khaliq H; Lehmkuhl HB; Yegitbasi M; Reinke P; Kebelmann-Betzig C; Hauptmann K; Gross-Wieltsch U; Hetzer R; Berger F
    Pediatr Transplant; 2009 Feb; 13(1):54-62. PubMed ID: 18518912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of patients with post-transplant lymphoproliferative disorder: the role of rituximab.
    Svoboda J; Kotloff R; Tsai DE
    Transpl Int; 2006 Apr; 19(4):259-69. PubMed ID: 16573540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early posttransplant lymphoproliferative disease in pediatric liver transplant recipients.
    Roque J; Rios G; Humeres R; Volpi C; Herrera JM; Schultz M; Rios H; Rius M; Salgado C; Hepp J
    Transplant Proc; 2006 Apr; 38(3):930-1. PubMed ID: 16647513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Posttransplant lymphoproliferative disorder after umbilical cord blood transplantation in children.
    Gong JZ; Bayerl MG; Sandhaus LM; Sebastian S; Rehder CW; Routbort M; Lagoo AS; Szabolcs P; Chiu J; Comito M; Buckley PJ
    Am J Surg Pathol; 2006 Mar; 30(3):328-36. PubMed ID: 16538052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-transplant lymphoproliferative disorders after live donor renal transplantation.
    Jain M; Badwal S; Pandey R; Srivastava A; Sharma RK; Gupta RK
    Clin Transplant; 2005 Oct; 19(5):668-73. PubMed ID: 16146560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Native kidney post-transplant lymphoproliferative disorder in a non-renal transplant patient.
    Araya CE; Mehta MB; González-Peralta RP; Hunger SP; Dharnidharka VR
    Pediatr Transplant; 2009 Jun; 13(4):495-8. PubMed ID: 18673359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful treatment of EBV PTLD with CNS lymphomas with the monoclonal anti-CD20 antibody rituximab.
    Kordelas L; Trenschel R; Koldehoff M; Elmaagacli A; Beelen DW
    Onkologie; 2008 Dec; 31(12):691-3. PubMed ID: 19060508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epstein-Barr viral load in whole blood of adults with posttransplant lymphoproliferative disorder after solid organ transplantation does not correlate with clinical course.
    Oertel S; Trappe RU; Zeidler K; Babel N; Reinke P; Hummel M; Jonas S; Papp-Vary M; Subklewe M; Dörken B; Riess H; Gärtner B
    Ann Hematol; 2006 Jul; 85(7):478-84. PubMed ID: 16586109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-CD20 monoclonal antibody (Rituximab) treatment for Epstein-Barr virus-associated, B-cell lymphoproliferative disease in pediatric liver transplant recipients.
    Serinet MO; Jacquemin E; Habes D; Debray D; Fabre M; Bernard O
    J Pediatr Gastroenterol Nutr; 2002 Apr; 34(4):389-93. PubMed ID: 11930095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fludarabine, cyclophosphamide, doxorubicin (FCD), and rituximab: a remission induction therapy for aggressive pediatric post-transplant lymphoproliferative disease (PTLD).
    Giraldi E; Provenzi M; Fiocchi R; Colledan M; Cornelli P; Torre G; Rambaldi A; Conter V
    Pediatr Blood Cancer; 2011 Aug; 57(2):324-8. PubMed ID: 21294246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-transplantation lymphoproliferative disorders localizing to the gastrointestinal tract after liver transplantation: report of five pediatric cases.
    Lai YC; Ni YH; Jou ST; Ho MC; Wu JF; Chen HL; Hu RH; Jeng YM; Chang MH; Lee PH
    Pediatr Transplant; 2006 May; 10(3):390-4. PubMed ID: 16677368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-transplant lymphoproliferative disorders in liver transplanted patients: a single-centre experience.
    Marino D; Burra P; Boccagni P; Calabrese F; Canova F; Trentin C; Boso C; Soldà C; Angeli P; Aversa SM
    Anticancer Res; 2010 Jun; 30(6):2383-91. PubMed ID: 20651397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complete response to post-transplant lymphoproliferative disorder by surgical resection and rituximab after living-donor liver re-transplantation for recurrent primary sclerosing cholangitis.
    Haruki K; Shiba H; Shimada J; Okui N; Iida T; Yanaga K
    Clin J Gastroenterol; 2017 Feb; 10(1):47-51. PubMed ID: 27796825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.